Jazz Pharmaceuticals (JAZZ) Is Up 10.4% After Record Q4 Revenue And New Oncology Data Release

• In late February 2026, Jazz Pharmaceuticals reported fourth‑quarter 2025 revenue of US$1,197.93 million and net income of US$203.45 million, contributing to record full‑year revenue of US$4.27 billion but a net loss of US$356.15 million.
• The company paired these results with guidance for 2026 revenue of US$4.25–4.50 billion and highlighted practice‑changing oncology data for zanidatamab and Ziihera, reinforcing its rare‑disease and cancer focus despite full‑year losses.
• Next, we’ll examine how record quarterly revenue alongside promising zanidatamab oncology data may reshape Jazz Pharmaceuticals’ existing investment narrative.

Rare earth metals are the new gold rush. Find out which 31 stocks are leading the charge.

Jazz Pharmaceuticals Investment Narrative Recap

To own Jazz Pharmaceuticals today, you need to believe its rare‑disease and oncology portfolio can offset pressure in the legacy sleep business and justify its high debt load. The latest results, with record 2025 revenue but a full‑year loss, keep the near‑term story centered on one catalyst: successful approval and launch of zanidatamab and Ziihera in oncology. The biggest risk remains execution and competition around oxybate and sleep therapies, and this quarter’s numbers do not fundamentally change that.

Against this backdrop, the most relevant update is management’s 2026 revenue guidance of US$4.25–4.50 billion, issued alongside Q4 2025 earnings. That range effectively ties the near‑term outlook to continued strength in Xywav, Epidiolex and Modeyso while investors wait for potential zanidatamab approval and launch in the second half of 2026. It neatly connects the current financial profile to the same oncology data that many see as key to reshaping Jazz’s story over the next few years.

Yet even with record sales, investors should be aware that looming generic oxybate pressure and Jazz’s high debt levels could still…

Read the full narrative on Jazz Pharmaceuticals (it’s free!)

Jazz Pharmaceuticals’ narrative projects $5.0 billion revenue and $883.5 million earnings by 2028.

Uncover how Jazz Pharmaceuticals’ forecasts yield a $219.40 fair value, a 15% upside to its current price.

Exploring Other Perspectives

Some of the lowest‑priced analysts came in more skeptical, assuming Jazz would reach only about US$4.6 billion of revenue and roughly US$645 million of earnings by 2028, so if you are weighing this latest oncology data against those more cautious views, it is worth remembering that reasonable people can look at the same company and see very different futures.

Explore 4 other fair value estimates on Jazz Pharmaceuticals – why the stock might be worth over 4x more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

Curious About Other Options?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com